Italian Journal of Medicine 2018-11-19T17:39:05+01:00 Paola Granata Open Journal Systems <p>The <strong>Italian Journal of Medicine (ITJM)</strong> is the official journal of FADOI, the Federation of Associations of Hospital Doctors on Internal Medicine and focus to describe the complex and variable situations confronted by Internists in daily practice. ITJM aims to promote excellence in the practice of internal medicine in hospitals and to disseminate the results of clinical research in internal medicine departments. The journal also contributes to the updating of hospital internists on general topics concerning public health, including ethical, legal, economical and health policy issues. The <strong>Italian Journal of Medicine (ITJM)</strong> is a quarterly peer-reviewed journal aiming to publish highest-quality material covering original basic and clinical research on all aspects of internal medicine. The Journal includes original clinical research papers, reviews, case reports and specific sections dedicated to clinical pharmacology, chronic diseases, health management. The Italian Journal of Medicine is currently indexed in <a title="Scopus" href="" target="_blank" rel="noopener">Scopus</a> and <a title="DOAJ" href="" target="_blank" rel="noopener">DOAJ</a> since September 2009.</p> L'internista naviga nel mare salato che è in noi 2018-11-19T17:39:02+01:00 Guest Editors: M. Grandi R. Frediani A. Fontanella P. Gnerre <p><img src="/public/site/images/pgranata/rass.jpg" alt=""><br><strong>Il mare vivo che è in noi</strong><br><em>F. Sgambato, S. Prozzo, E. Sgambato<br><br></em><strong>Meccanismi fisiologici del ricambio di sodio ed acqua</strong><br><em>M. Renis<br><br></em><strong>Le alterazioni del bilancio del sodio e dell’acqua</strong><br><em>M. Renis<br><br></em><strong>Approccio clinico-pratico ai disturbi dell’equilibrio acido-base</strong><br><em>A. Casola, L. Bianchi, S. Detrenis, S. Pioli, M. del Mar Jordana-Sanchez, T. Pasquariello, D. Fasano, M. Saccò, A. Magnano, F. Spagnoli, M. Meschi<br></em><em><img src="/public/site/images/pgranata/Sezioni5.jpg"><br></em><strong>Approccio clinico-diagnostico e strumentale alle iposodiemie ipotoniche e non ipotoniche</strong><br><em>I. Ambrosino<br><br></em><strong>Approccio clinico-diagnostico e strumentale alle ipersodiemie</strong><br><em>A. Ilardi<br><br></em><strong>La sindrome da inappropriata antidiuresi</strong><br><em>G. Tenconi, G. Secondo, L. Mortara<br></em><em><img src="/public/site/images/pgranata/Sezioni6.jpg"><br></em><strong>Approccio clinico-diagnostico e strumentale alle ipopotassiemie</strong><br><em>T.M. Attardo<br><br></em><strong>Approccio diagnostico e strumentale alle iperpotassiemie</strong><br><em>M. Gambacorta<br></em><em><img src="/public/site/images/pgranata/Sezioni7.jpg"><br></em><strong>Ipocalcemia: condizione comune a diverse patologie</strong><br><em>A. Montagnani, M. Alessandri, M. Migliorini<br><br></em><strong>Approccio clinico-diagnostico e strumentale alle ipercalcemie</strong><br><em>P. Gnerre, M. Grandi, A. Percivale<br><br></em><em><img src="/public/site/images/pgranata/Sezioni8.jpg"><br></em><strong>Approccio clinico-diagnostico e strumentale alle ipomagnesiemie e alle ipermagnesiemie</strong><br><em>L. Lenzi<br><br></em><em><img src="/public/site/images/pgranata/Sezioni9.jpg"><br></em><strong>Approccio al paziente con ipofosfatemia e iperfosfatemia</strong><br><em>M.T. De Donato<br><br></em><img src="/public/site/images/pgranata/concl.jpg" alt=""><br><strong>Conclusioni <br><em> hai sale in zucca?</em></strong><br><em>A. Fontanella</em></p> 2018-11-12T12:33:08+01:00 ##submission.copyrightStatement## Nursing clinical competence in area medica 2018-11-19T17:39:04+01:00 Guest Editors: F. Bertoncini C. Gatta G. Pentella <p><strong>Introduzione</strong><br> <strong>Background</strong></p> <ul> <li><em>La nursing clinical competence</em></li> <li><em>Il concetto di clinical competence in medicina interna</em></li> <li><em>Declinare e classificare i livelli di competenza</em></li> <li><em>Aree di assistenza nei contesti di area medica</em><br>&nbsp; <ul> <li>Il paziente cronico</li> <li>Scompenso cardiaco</li> <li>La broncopneumopatia cronica e ostruttiva</li> <li>La cirrosi epatica</li> <li>La pancreatite</li> <li>Il diabete mellito</li> <li>Il delirium</li> <li>La depressione</li> <li>Il paziente critico</li> <li>L’ipertensione</li> <li>La trombosi venosa profonda</li> <li>L’ischemia cerebrale</li> <li>La disfagia</li> <li>Gli squilibri idroelettrolitici</li> <li>Le polmoniti</li> <li>I sanguinamenti gastro-intestinali</li> <li>La sepsi</li> <li>Il monitoraggio cardiaco</li> <li>La ventilazione non-invasiva</li> <li>L’ecografia operativa bedside</li> <li>Somministrazione di terapia e chemioterapia</li> <li>Le lesioni da pressione</li> <li>Il dolore</li> <li>Gli accessi vascolari</li> <li>Il paziente fragile</li> <li>La dimissione difficile</li> <li>Il fine vita</li> </ul> </li> </ul> <p><strong>Obiettivo</strong><br> <strong>Metodi</strong><br> <strong>Risultati</strong><br> <strong>Conclusioni</strong><br> <strong>Bibliografia</strong></p> 2018-10-24T09:35:54+02:00 ##submission.copyrightStatement## Optimal duration of anticoagulant therapy in patients with venous thromboembolism 2018-11-19T17:39:05+01:00 Gualtiero Palareti <p>Venous thromboembolism (VTE), a frequent and severe disease, has clinically important early and late complications and a strong tendency to recur. Anticoagulant therapy is the mainstay of treatment, performed by immediate administration of: a) parenteral anticoagulants followed by vitamin K antagonists (VKAs), either dabigatran or edoxaban, two direct oral anticoagulants (DOACs); or b) direct rivaroxaban or apixaban, two DOACs that can be used as single-drug approach. Treatment should last no less than 3 months in all patients though how long it should last thereafter is a more complex issue. The risk of recurrence results from several event- or patient-associated factors. Some patients have low risk and may be treated for 3 to 6 months only. Others (the majority), have a high risk of recurrence (approximately 50% in 10 years). Unfortunately, the protective effect of anticoagulation against recurrence is present only during treatment and is lost when therapy is stopped. For this reason, international guidelines recommend there be no pre-definite period of anticoagulation (e.g. 1 or 2 years, and so on) in patients at high risk and suggest instead indefinite (extended) anticoagulation, provided there is no high risk of bleeding. When the decision is difficult, adjunctive criteria may be adopted, such as male sex and abnormal Ddimer assessed after anticoagulation is stopped, to identify patients at high risk who need indefinite therapy. The use of DOACs, especially at lower doses with a lower risk of bleeding, may make indefinite anticoagulation for patients easier.</p> 2018-09-14T17:43:39+02:00 ##submission.copyrightStatement##